Although programmed cell death 1 inhibitors have demonstrated efficacy in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, their application in TBSCC remains underexplored. The gene discussed is PDCD1; the disease is cutaneous squamous cell carcinoma.